When people describe a psilocybin experience, they often reach for words like “mind-expanding” and “consciousness-altering.” Scientists at Imperial College London decided to look inside the brain during these experiences to understand what was actually happening at a neurological level — and what they found challenged longstanding assumptions about how psychedelics work.
Psilocybin Quiets the Brain Rather Than Activating It
The prevailing theory had been that hallucinogenic substances like psilocybin worked by increasing blood flow to the brain and creating new connections between regions. Researchers expected to see heightened neural activity. Instead, the opposite occurred.
Brain imaging revealed that psilocybin suppressed activity in several critical areas, including the anterior cingulate cortex, the medial prefrontal cortex, and the posterior cingulate cortex. These regions play key roles in regulating self-awareness, integrating sensory information with the sense of being present in time, and maintaining what neuroscientists call the “default mode network” — a system believed to sustain our baseline sense of ego and self-reflection.
The more these brain regions were suppressed, the more intensely participants reported changes in their perception. This finding aligned with a decades-old hypothesis from British author Aldous Huxley, who speculated that hallucinogens worked not by adding something to consciousness, but by removing the brain’s natural filtering mechanisms — essentially taking the brakes off perception.
How the Study Was Conducted
David Nutt, professor of neuropsychopharmacology at Imperial College London, and his team recruited 15 healthy volunteers who had previous experience with hallucinogenic substances. Over two days, participants lay in a brain scanner for sessions lasting up to an hour. On the first day, they received a placebo injection. On the second day, they received an intravenous dose of psilocybin calibrated to peak at about four minutes and largely dissipate within 30 minutes.
No participant had difficulty distinguishing the real drug from the placebo. All reported vivid kaleidoscopic vision with bright, angular shapes. The initial rush during the first 10 to 30 seconds produced some anxiety, but positive feelings quickly took over. Participants described sensations of being transported elsewhere, of feeling fragmented or stretched across space. One participant reported the experience of kneeling at the feet of God. Others described a profound sense of unity with the universe.
Implications for Treating Depression
The specific brain regions that psilocybin suppressed turned out to be highly relevant to psychiatric research. The anterior cingulate cortex, one of the areas most affected, is known to be hyperactive in people with clinical depression. Some existing treatments for severe, treatment-resistant depression actually involve implanting electrodes in this region to reduce its activity.
Nutt pointed out that psilocybin achieved a similar suppression effect through pharmacological means — a potentially far simpler and less invasive approach than surgical electrode placement. His team published a companion study in The British Journal of Psychiatry showing that guiding participants to reflect positively on past experiences while under psilocybin’s influence produced a measurable improvement in well-being that persisted for at least two weeks afterward.
Supporting Evidence From Johns Hopkins
Roland Griffiths, a neuroscientist and psychopharmacologist at Johns Hopkins University, noted that the Imperial College findings complemented his own research. His studies had shown that participants who received carefully measured psilocybin doses in controlled settings reported feeling happier, calmer, and more at peace more than a year later. Griffiths was at the time conducting clinical trials with cancer patients experiencing anxiety and depression, exploring whether psilocybin could provide lasting psychological relief.
The Risks Are Real Outside Clinical Settings
Both Nutt and Griffiths emphasized that the controlled conditions of their research were essential to the positive outcomes they observed. Outside a supervised clinical environment, psilocybin carries genuine risks. Depending on the dose, the individual’s mental state, and the setting, the drug can trigger panic reactions and lead to behavior that endangers the user or others.
Griffiths acknowledged that while there may be legitimate therapeutic applications for psilocybin, the substance is unlikely to become something people can simply pick up at a pharmacy. The gap between a carefully managed clinical session with trained guides and the unpredictable circumstances of recreational use is significant enough that widespread over-the-counter availability would raise serious safety concerns.
A New Direction for Psychedelic Neuroscience
The Imperial College research, published in the Proceedings of the National Academy of Sciences, represented an important step in understanding both the mechanisms of psychedelic experience and its potential clinical applications. By demonstrating that psilocybin works by suppressing rather than stimulating brain activity — and that this suppression targets regions implicated in depression — the study opened a new avenue for psychiatric treatment research.
Nutt planned to follow up with studies combining psilocybin with guided therapy for patients with enduring depression, particularly those locked into persistently negative thought patterns that conventional treatments had failed to break. The goal was not to replace existing antidepressants but to explore whether a single carefully administered psychedelic session could help reset dysfunctional neural patterns in ways that ongoing medication cannot.
